| Pane, Fabrizio |
| Active, not recruiting | 4 | 450 | Europe | Imatinib, Nilotinib | Gruppo Italiano Malattie EMatologiche dell'Adulto | Chronyc Myeloid Leukemia | 02/23 | 02/24 | | |
NCT04168502: Gemtuzumab Chemotherapy MRD Levels; Adult Untreated, de Novo, Fav Interm Risk AML |
|
|
| Recruiting | 3 | 414 | Europe | Gemtuzumab Ozogamicin | Gruppo Italiano Malattie EMatologiche dell'Adulto | Acute Myeloid Leukemia | 04/25 | 04/27 | | |
KRdvsRd, NCT04096066: A Trial That Compare Two Treatments in Newly Diagnosed Myeloma Patients Not Eligible for Transplant |
|
|
| Active, not recruiting | 3 | 84 | Europe | Carfilzomib, Kyprolis, Lenalidomide, Revlimid, Dexamethasone | Fondazione EMN Italy Onlus | Multiple Myeloma, New Diagnosis Tumor | 07/24 | 07/24 | | |
| Recruiting | 3 | 322 | Europe, Canada, US | Crenolanib, Crenolanib besylate, Cytarabine, Mitoxantrone, Placebo Oral Tablet, Fludarabine, Idarubicin, G-CSF | Arog Pharmaceuticals, Inc. | Relapsed/Refractory Acute Myeloid Leukemia With FLT3 Activating Mutations | 10/24 | 10/24 | | |
| Active, not recruiting | 3 | 240 | Europe, Canada, US, RoW | Brentuximab vedotin, Rituximab, Lenalidomide, Placebo | Seagen Inc. | Diffuse Large B-cell Lymphoma | 05/25 | 04/27 | | |
|
DESTINY, NCT05334368: Depemokimab in Participants With Hypereosinophilic Syndrome, Efficacy, and Safety Trial |
|
|
| Recruiting | 3 | 120 | Europe, Canada, Japan, US, RoW | Depemokimab, Placebo | GlaxoSmithKline | Hypereosinophilic Syndrome | 02/26 | 03/26 | | |
SYMPHONY-1, NCT04224493 / 2019-003333-42: A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus Rituximab Versus Placebo in Combination With Lenalidomide Plus Rituximab in Adult Patients at Least 18 Years of Age With Relapsed/Refractory Follicular Lymphoma. |
|
|
| Recruiting | 3 | 612 | Europe, Canada, US, RoW | Tazemetostat, EPZ-6438, IPN60200, Placebo oral tablet, Lenalidomide, Rituximab | Epizyme, Inc. | Relapsed/Refractory Follicular Lymphoma, Follicular Lymphoma, Refractory Follicular Lymphoma | 03/26 | 03/29 | | |
|
|
|
|
|
|
|
OLYMPIA-2, NCT06097364: A Trial to Learn if Odronextamab Combined With Chemotherapy is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Chemotherapy for Adult Participants With Follicular Lymphoma |
|
|
| Recruiting | 3 | 733 | Europe, US, RoW | Odronextamab, REGN1979, Rituximab, Rituxan, Cyclophosphamide, Cytoxan, Doxorubicin, Adriamycin, Vincristine, Oncovin, Prednisone/Prenisolone, Deltasone/Omnipred | Regeneron Pharmaceuticals | Follicular Lymphoma (FL) | 07/29 | 07/29 | | |
FIL_GAZEBO, NCT05929222: Comparison Between Local Radiotherapy Alone or Combined With Obinutuzumab in Early Stage Follicular Lymphoma: the GAZEBO Trial From the Fondazione Italiana Linfomi |
|
|
| Recruiting | 3 | 190 | Europe | Radiotherapy, Radiotherapy plus Obinutuzumab | Fondazione Italiana Linfomi - ETS, Roche Pharma AG | Follicular Lymphoma | 04/31 | 04/31 | | |
NCT04475731: Ponatinib in Adult Ph+ ALL Patients With MRD Positivity or Hematological Relapse |
|
|
| Active, not recruiting | 2 | 67 | Europe | Ponatinib | Gruppo Italiano Malattie EMatologiche dell'Adulto | Philadelphia-Positive ALL, Acute Lymphoblastic Leukemia, in Relapse | 11/24 | 11/24 | | |
GITMO-PHYLOS, NCT03270748: Post Transplant High-Dose Cy as GvHD Prophylaxis in 1 HLA Mismatched Unrelated HSCT for Myeloid Malignancies |
|
|
| Completed | 2 | 78 | Europe | GvHD prophylaxis | Gruppo Italiano Trapianto di Midollo Osseo | Myeloid Malignancies | 11/22 | 11/22 | | |
CLL1818, NCT03804372 / 2019-000159-14: The Incidence of Hepatitis B in Diffuse Large B-Cell Lymphoma/Chronic Lymphoid Leukemia HBsAg-positive Treated With Rituximab, Chemotherapy and Tenofovir Alafenamide |
|
|
| Active, not recruiting | 2 | 5 | Europe | Rituximab, Chemotherapy, Tenofovir alafenamide | Gruppo Italiano Malattie EMatologiche dell'Adulto | Large-B-cell Diffuse Lymphoma, Chronic Lymphoid Leukemia | 11/24 | 11/24 | | |
Phoenix, NCT05924100: Efficacy and Safety of Luspatercept for the Treatment of Anemia Due to MDS With del5q, Refractory/Resistant/Intolerant to Prior Treatments, RBC-TD |
|
|
| Recruiting | 2 | 22 | Europe | Luspatercept Injection [Reblozyl] | Associazione Qol-one | Myelodysplastic Syndromes, Del(5Q), Anemia, Transfusion-dependent Anemia | 12/24 | 12/29 | | |
| Completed | 2 | 41 | Europe, Japan, US, RoW | Placebo, TAK-079 | Takeda | Primary Immune Thrombocytopenia | 04/24 | 04/24 | | |
NCT05306301: Ponatinib Plus Chemotherapy in Acute Lymphoblastic Leukemia Patients |
|
|
| Recruiting | 2 | 32 | Europe | Ponatinib | Gruppo Italiano Malattie EMatologiche dell'Adulto | Chemotherapy, Leukemia, Acute Lymphoblastic | 02/25 | 07/28 | | |
| Completed | 1 | 15 | Europe, US, RoW | Modakafusp alfa, TAK-573, Lenalidomide, Bortezomib, Carfilzomib, Daratumumab, Pomalidomide | Takeda | Multiple Myeloma | 01/24 | 06/24 | | |
| Recruiting | N/A | 343 | Europe, RoW | Questionnaire | Gruppo Italiano Malattie EMatologiche dell'Adulto, European Organisation for Research and Treatment of Cancer - EORTC | Acute Myeloid Leukemia | 06/21 | 12/22 | | |
NCT06506084: Observational Study on the Use of Ropeginterferon Alfa-2b in Polycythemia Vera (ROPEG-PV) |
|
|
| Recruiting | N/A | 319 | Europe | Ropeginterferon alfa-2b, Besremi | FROM- Fondazione per la Ricerca Ospedale di Bergamo- ETS | Polycythemia Vera | 09/24 | 12/26 | | |
NCT04352556: COVID19-hematological Malignancies: the Italian Hematology Alliance |
|
|
| Recruiting | N/A | 250 | Europe | | Ospedale di Circolo - Fondazione Macchi | SARS-CoV-2 Infection, Hematological Malignancies | 10/22 | 10/22 | | |
CML1012, NCT01752062: Observational Study of Conception/Pregnancy in Adult Patients With CML Treated With Tyrosine Kinase Inhibitors |
|
|
| Recruiting | N/A | 148 | Europe | | Gruppo Italiano Malattie EMatologiche dell'Adulto | Chronic Myeloid Leukemia, Pregnancy | 12/22 | 12/22 | | |
| Recruiting | N/A | 861 | Europe | Observation | Gruppo Italiano Malattie EMatologiche dell'Adulto, Hematology Project Foundation | Idiopathic Thrombocytopenic Purpura | 07/23 | 07/23 | | |
| Recruiting | N/A | 190 | Europe | acalabrutinib, Calquence | AstraZeneca, Yghea | Chronic Lymphocytic Leukemia | 02/30 | 02/30 | | |
| Recruiting | N/A | 1900 | Europe | Observation | Fondazione EMN Italy Onlus | Multiple Myeloma | 03/24 | 03/24 | | |
| Not yet recruiting | N/A | 617 | Europe, RoW | | FROM- Fondazione per la Ricerca Ospedale di Bergamo- ETS, GlaxoSmithKline | Myelofibrosis | 12/24 | 12/28 | | |
FIL_MIMYC, NCT06588205: Exploring the Clinical Impact of MYC Aberrations and Their Relationship With Microenvironment in Diffuse Large B Cell Lymphoma and High-Grade B Cell Lymphoma |
|
|
| Not yet recruiting | N/A | 200 | Europe | | Fondazione Italiana Linfomi - ETS | Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma, High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements | 12/27 | 12/27 | | |
FIL_MAB, NCT06008691: A Prospective, Observational Cohort Study on the Clinical Impact of Novel Monoclonal Antibodies in B-cell Non-Hodgkin Lymphoma in Italian Clinical Practice |
|
|
| Recruiting | N/A | 1500 | Europe | "novel" MAB (alone or in combination) | Fondazione Italiana Linfomi - ETS, Roche Pharma AG | Non-Hodgkin Lymphoma, B-cell | 10/38 | 10/38 | | |
